Clin Exp Pediatr.
2023 May;66(5):182-189. 10.3345/cep.2022.00878.
COVID-19 in immunocompromised children and adolescents
- Affiliations
-
- 1Department of Pediatrics, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea
- 2Department of Pediatrics, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea
- KMID: 2541867
- DOI: http://doi.org/10.3345/cep.2022.00878
Abstract
- Since coronavirus disease 2019 (COVID-19) became a global pandemic, concerns have arisen regarding the risks of COVID-19 in immunocompromised children and adolescents. Here we aimed to evaluate the clinical outcomes and risks of severe COVID-19 in immunocompromised pediatric patients. Previous studies reported that most children and adolescents receiving immunosuppressive medications have clinical presentations and favorable outcomes similar to those of the general pediatric population. Treatments and access to health services should not be interrupted in these populations, and continuous monitoring of the potential impact of variant strains on the risk of immunocompromised pediatric patients is warranted.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Therapeutics in the Treatment of COVID-19 for Children and Adolescents
- Kidney complications associated with COVID-19 infection and vaccination in children and adolescents: a brief review
- Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents
- The Effects of COVID-19 on the Self-Harm in Children and Adolescents Observed in a University Hospital
- Adverse reactions to coronavirus disease 2019 vaccines in children and adolescents
